Work

Q-TWiST analysis of pembrolizumab plus trastuzumab and chemotherapy for patients with metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma in the KEYNOTE-811 trial.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.4_suppl.354

Authors: Sun Young Rha, Cedric Revil, Adriana Valderrama, Liya Wang, Manon Andre, Grant McCarthy, Kate Young

Institutions: Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, MSD (Switzerland), Merck & Co., Inc., Rahway, NJ, USA (United States), MSD (UK) Limited (United Kingdom)

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4406869868

Cites:

Cited by: 1

Related to: 10